• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Genetic Testing in Depression

Genetic Testing in Depression

September 10, 2021
Thomas Jordan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD. Dr. Jordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Perlis RH et al, Depress Anxiety 2020;37(9):834–841

STUDY TYPE: Randomized controlled trial

By tailoring medications to a patient’s genetic profile, pharmacogenomics promises less medication trial and error, fewer side effects, and better overall outcomes. But does knowing a patient’s pharmacogenetic profile really improve treatment for some of the most common illnesses that we see, like depression? So far the controlled trials have been largely negative, but they’ve mainly focused on the Genesight panel. This trial tested the Genecept panel, which includes most of the genes in the Genesight panel but adds a few pharmacodynamic elements that have only preliminary evidence for use (eg, BDNF, melanocortin, and major histocompatibility complex).

This randomized controlled trial enrolled 314 adults with moderate to severe major depressive disorder who had already failed 1–3 antidepressant medications in the current depressive episode. Half the patients received treatment that was actively guided by the test, while the other half received treatment as usual. The primary outcome, change in Hamilton Depression Rating Scale score, was measured over eight weeks of treatment. The patients and researchers performing the rating scales were blinded to the treatment arm assignment, but the treating provider was not blinded.

At the end of the trial, the changes in depression scores (p = 0.53), rates of response (p = 0.17), and rates of remission (p = 0.23) were all no different between the two groups. Most of the secondary outcomes also showed no difference between the groups, including a self-report rating scale, the Clinical Global Impression-Improvement scale, and patient rating of side effects.

The authors did find that patients were more likely to remit when their medications were concordant with their test results. This finding, however, was only positive on post-hoc analysis, which means it is prone to false positives and should be interpreted with caution.

TCPR’s Take
Genecept joins the list of companies that have failed to show any benefit associated with genetic testing, even in patients who did not respond to one or more antidepressants. While this does not support the routine use of genetic testing, it doesn’t mean the tests do nothing. Consistent with earlier studies, patients fared worse when their medications were misaligned with their genetic results, but those misalignments are likely too rare to make a measurable difference.
General Psychiatry
KEYWORDS genesight genetic-testing genetics_and_psychiatry pharmacogenomics randomized-controlled-trial research research-update
Thomas Jordan, MD.

Does Baclofen Titrated to High Doses Reduce Alcohol Use?

More from this author
www.thecarlatreport.com
Issue Date: September 10, 2021
SUBSCRIBE NOW
Table Of Contents
Genetic Testing in Depression
Desert Island Diagnoses
Atomoxetine: Myths and Truths
Overdiagnosis in Psychiatry
Psilocybin vs Escitalopram for Depression
Pilot Study of Ketamine vs ECT for Major Depression
CME Post-Test - Overdiagnosis, TCPR, September 2021
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.